medical device investing Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test
medical device investing Chembio Diagnostics and LumiraDx Enter Collaboration to Develop New Point-of-Care Diagnostic Tests for Infectious Diseases
medical device investing Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property